or Try an Advanced Search...

    Gabaa Receptor Positive Allosteric Modulators Stocks List

    Symbol Grade Name % Change
    ESPR B Esperion Therapeutics, Inc. 2.70
    AQST D Aquestive Therapeutics, Inc. -3.27
    SAGE F Sage Therapeutics, Inc. 2.04
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Drugs Seizure Adjunctive Therapy Amyotrophic Lateral Sclerosis Anaphylaxis Anticonvulsants Antidepressants Atherosclerosis Cardiology Central Nervous System Disorders Chloroarenes Cholesterol Clinical Development Diabetes Disease Epilepsy Lipid Lipoprotein Low Density Lipoprotein

    Related ETFs - A few ETFs which own one or more of the above listed Gabaa Receptor Positive Allosteric Modulators stocks.

    Symbol Grade Name Weight
    PSIL C AdvisorShares Psychedelics ETF 4.78
    JFWD B Jacob Funds Inc. Jacob Forward ETF 4.67
    BBP C BioShares Biotechnology Products Fund 1.92
    QQQS C Invesco NASDAQ Future Gen 200 ETF 0.86
    BIS B ProShares UltraShort Nasdaq Biotechnology 0.67
    View all Gabaa Receptor Positive Allosteric Modulators ETFs...
    Compare ETFs
    Compare BBP to QQQS Compare JFWD to QQQS Compare PSIL to BIS

        Gabaa Receptor Positive Allosteric Modulators Stocks Recent News

        Date Stock Title
        Nov 21 SAGE Sage ends dalzanemdor development following Phase II trial failure
        Nov 21 SAGE SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study
        Nov 21 SAGE Sage raised to sector perform by RBC in wake of drug failure
        Nov 21 ESPR Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
        Nov 20 SAGE After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
        Nov 20 SAGE Sage slips as Huntington’s Disease therapy fails in mid-stage trial
        Nov 20 SAGE Sage’s string of research failures continues
        Nov 20 SAGE Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
        Nov 19 SAGE CNS Drug Development: Same As It Ever Was
        Nov 18 ESPR Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
        Nov 16 AQST Is Aquestive Therapeutics (AQST) the Best Multibagger Stock to Buy Heading into 2025?
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Drugs Seizure Adjunctive Therapy Amyotrophic Lateral Sclerosis Anaphylaxis Anticonvulsants Antidepressants Atherosclerosis Cardiology Central Nervous System Disorders Chloroarenes Cholesterol Clinical Development Diabetes Disease Epilepsy Lipid Lipoprotein Low Density Lipoprotein
        Gabaa Receptor Positive Allosteric Modulators

        GABAA Receptor Positive Allosteric Modulators (PAMs) are a class of drugs that act on the GABA-A receptor to enhance its activity. These drugs are used to treat a variety of conditions, including anxiety, insomnia, epilepsy, and alcohol withdrawal. They work by increasing the activity of the GABA-A receptor, which helps to reduce the excitability of neurons in the brain and promote relaxation.

        Browse All Tags